2018-003779-36: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss. |
|
|
| Not yet recruiting | 2 | 116 | Europe | AZD6738, Olaparib (Lynparza), AZD6738, Olaparib (AZD2281), Film-coated tablet, Olaparib (Lynparza) | The Institute of Cancer Research, AstraZeneca UK Limited, Lady Garden Foundation | Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma (squamous and adenocarcinoma), Relapsed gynaecological cancers of rare subtypes, including clear cell (ovarian/uterus) and carcinosarcoma, cervical and endometrioid type., Diseases [C] - Cancer [C04] | | | | |
NCT04417062: Olaparib With Ceralasertib in Recurrent Osteosarcoma |
|
|
| Recruiting | 2 | 63 | US | Olaparib, Lynparza, Ceralasertib, AZD6738 | Dana-Farber Cancer Institute, Osteosarcoma Institute, AstraZeneca | Osteosarcoma, Osteosarcoma Recurrent | 06/24 | 06/25 | | |
